Tharimmune (THAR) Competitors $1.76 0.00 (0.00%) Closing price 03:50 PM EasternExtended Trading$1.79 +0.03 (+1.65%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock THAR vs. BIVI, RVPH, CING, JATT, MTEX, QTTB, MRKR, LPCN, CARM, and PRPHShould you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include BioVie (BIVI), Reviva Pharmaceuticals (RVPH), Cingulate (CING), JATT Acquisition (JATT), Mannatech (MTEX), Q32 Bio (QTTB), Marker Therapeutics (MRKR), Lipocine (LPCN), Carisma Therapeutics (CARM), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry. Tharimmune vs. Its Competitors BioVie Reviva Pharmaceuticals Cingulate JATT Acquisition Mannatech Q32 Bio Marker Therapeutics Lipocine Carisma Therapeutics ProPhase Labs BioVie (NASDAQ:BIVI) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends. Do analysts prefer BIVI or THAR? Tharimmune has a consensus price target of $17.00, suggesting a potential upside of 865.91%. Given Tharimmune's higher possible upside, analysts clearly believe Tharimmune is more favorable than BioVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00Tharimmune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has better earnings and valuation, BIVI or THAR? BioVie is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioVieN/AN/A-$32.12M-$7.91-1.02TharimmuneN/AN/A-$12.20M-$7.88-0.22 Does the media favor BIVI or THAR? In the previous week, BioVie had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for BioVie and 0 mentions for Tharimmune. BioVie's average media sentiment score of 0.86 beat Tharimmune's score of 0.00 indicating that BioVie is being referred to more favorably in the media. Company Overall Sentiment BioVie Positive Tharimmune Neutral Is BIVI or THAR more profitable? BioVie's return on equity of -100.88% beat Tharimmune's return on equity.Company Net Margins Return on Equity Return on Assets BioVieN/A -100.88% -78.49% Tharimmune N/A -489.33%-264.34% Which has more risk & volatility, BIVI or THAR? BioVie has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Do insiders and institutionals have more ownership in BIVI or THAR? 4.6% of BioVie shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 2.4% of BioVie shares are held by insiders. Comparatively, 10.0% of Tharimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryBioVie beats Tharimmune on 7 of the 13 factors compared between the two stocks. Get Tharimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THAR vs. The Competition Export to ExcelMetricTharimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.68M$2.90B$5.51B$8.96BDividend YieldN/A2.44%5.25%4.02%P/E Ratio-0.2221.0128.0520.16Price / SalesN/A295.02438.35127.91Price / CashN/A41.8337.0657.97Price / Book2.597.868.125.62Net Income-$12.20M-$54.95M$3.16B$248.50M7 Day Performance-3.30%6.24%4.40%5.54%1 Month Performance10.00%5.70%4.09%7.52%1 Year Performance-49.86%8.08%34.53%22.06% Tharimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THARTharimmune2.7736 of 5 stars$1.76flat$17.00+865.9%-48.8%$4.68MN/A-0.222BIVIBioVie0.7083 of 5 stars$0.99+5.8%N/A+111.8%$18.29MN/A-0.1210News CoverageRVPHReviva Pharmaceuticals2.2824 of 5 stars$0.38+2.9%$9.00+2,268.4%-69.4%$18.24MN/A-0.485CINGCingulate2.9214 of 5 stars$4.27+3.1%$26.00+508.9%+1,135.6%$18.15MN/A-0.5020News CoveragePositive NewsJATTJATT AcquisitionN/A$1.05flatN/A-67.7%$18.11MN/A0.003Gap UpHigh Trading VolumeMTEXMannatech0.2856 of 5 stars$9.45+2.9%N/A+17.5%$17.96M$117.87M-94.50250Gap UpQTTBQ32 Bio2.0324 of 5 stars$1.46+1.7%$12.17+731.1%-92.7%$17.81M$1.16M-0.3039MRKRMarker Therapeutics3.667 of 5 stars$1.57+4.0%$13.17+738.6%-65.6%$17.76M$6.59M-1.1860Positive NewsLPCNLipocine1.554 of 5 stars$3.21+0.5%$9.00+180.8%-57.8%$17.15M$11.20M-3.1410CARMCarisma Therapeutics2.3948 of 5 stars$0.41+0.5%$1.93+373.0%-66.2%$17.05M$19.63M-0.2620PRPHProPhase LabsN/A$0.40+5.0%N/A-87.1%$16.66M$6.77M-0.32130 Related Companies and Tools Related Companies BioVie Competitors Reviva Pharmaceuticals Competitors Cingulate Competitors JATT Acquisition Competitors Mannatech Competitors Q32 Bio Competitors Marker Therapeutics Competitors Lipocine Competitors Carisma Therapeutics Competitors ProPhase Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THAR) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.